Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Assets (2022 - 2025)

Historic Assets for Atara Biotherapeutics (ATRA) over the last 4 years, with Q3 2025 value amounting to $30.2 million.

  • Atara Biotherapeutics' Assets fell 7886.07% to $30.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.2 million, marking a year-over-year decrease of 7886.07%. This contributed to the annual value of $109.1 million for FY2024, which is 3408.14% down from last year.
  • Latest data reveals that Atara Biotherapeutics reported Assets of $30.2 million as of Q3 2025, which was down 7886.07% from $36.9 million recorded in Q2 2025.
  • In the past 5 years, Atara Biotherapeutics' Assets registered a high of $436.1 million during Q2 2022, and its lowest value of $30.2 million during Q3 2025.
  • Moreover, its 4-year median value for Assets was $165.5 million (2023), whereas its average is $209.6 million.
  • Per our database at Business Quant, Atara Biotherapeutics' Assets plummeted by 2396.22% in 2023 and then plummeted by 7886.07% in 2025.
  • Quarter analysis of 4 years shows Atara Biotherapeutics' Assets stood at $376.4 million in 2022, then crashed by 56.03% to $165.5 million in 2023, then tumbled by 34.08% to $109.1 million in 2024, then tumbled by 72.35% to $30.2 million in 2025.
  • Its last three reported values are $30.2 million in Q3 2025, $36.9 million for Q2 2025, and $62.0 million during Q1 2025.